Disc Medicine (NASDAQ:IRON) COO Jonathan Yen-Wen Yu Sells 8,796 Shares

Key Points

• COO Jonathan Yen-Wen Yu sold 8,796 Disc Medicine shares at an average price of $83.12, generating $731,123.52 and reducing his position by 13.94% to 54,324 shares.
• Disc Medicine shares rose 0.3% to $82.67, while the company reported a quarterly loss of $1.54 per share—better than analysts’ $1.71 loss estimate.
• Analysts maintain a “Moderate Buy” consensus, with an average price target of $106.50; institutional investors own 83.70% of the company.

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) COO Jonathan Yen-Wen Yu sold 8,796 shares of the firm's stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $83.12, for a total transaction of $731,123.52. Following the sale, the chief operating officer owned 54,324 shares in the company, valued at approximately $4,515,410.88. This trade represents a 13.94% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Jonathan Yen-Wen Yu also recently made the following trade(s):

• On Monday, August 24th, Jonathan Yen-Wen Yu sold 300 shares of Disc Medicine stock. The stock was sold at an average price of $82.53, for a total transaction of $24,759.00.
• On Wednesday, August 12th, Jonathan Yen-Wen Yu sold 804 shares of Disc Medicine stock. The shares were sold at an average price of $82.64, for a total value of $66,442.56.
• On Tuesday, July 7th, Jonathan Yen-Wen Yu sold 100 shares of Disc Medicine stock. The shares were sold at an average price of $82.50, for a total transaction of $8,250.00.
• On Friday, June 26th, Jonathan Yen-Wen Yu sold 300 shares of Disc Medicine stock. The stock was sold at an average price of $72.50, for a total value of $21,750.00.
• On Monday, June 22nd, Jonathan Yen-Wen Yu sold 9,700 shares of Disc Medicine stock. The shares were sold at an average price of $72.66, for a total transaction of $704,802.00.
• On Tuesday, June 16th, Jonathan Yen-Wen Yu sold 18,612 shares of Disc Medicine stock. The stock was sold at an average price of $69.19, for a total value of $1,287,764.28.

Disc Medicine Stock Up 0.3%

Shares of NASDAQ IRON traded up $0.26 on Wednesday, reaching $82.67. 586,890 shares of the company's stock traded hands, compared to its average volume of 329,310. Disc Medicine, Inc. has a 12 month low of $40.00 and a 12 month high of $99.50. The company has a quick ratio of 24.14, a current ratio of 24.14 and a debt-to-equity ratio of 0.09. The company has a market cap of $316.63 million, a price-to-earnings ratio of -12.56 and a beta of 1.00. The business's 50 day simple moving average is $76.56 and its two-hundred day simple moving average is $69.95.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share for the quarter, beating the consensus estimate of ($1.71) by $0.17. As a group, equities research analysts forecast that Disc Medicine, Inc. will post -6.61 EPS for the current fiscal year.

Institutional Trading of Disc Medicine

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. California State Teachers Retirement System raised its position in shares of Disc Medicine by 8,273.0% during the second quarter. California State Teachers Retirement System now owns 2,878,790 shares of the company's stock valued at $210,555,000 after buying an additional 2,844,408 shares during the last quarter. AXQ Capital LP bought a new stake in Disc Medicine in the 2nd quarter valued at $441,000. Nykredit A S bought a new stake in Disc Medicine in the 2nd quarter valued at $103,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Disc Medicine by 2.9% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 114,109 shares of the company's stock worth $8,346,000 after purchasing an additional 3,219 shares in the last quarter. Finally, Wellington Management Group LLP boosted its holdings in shares of Disc Medicine by 0.3% during the 2nd quarter. Wellington Management Group LLP now owns 1,741,351 shares of the company's stock valued at $127,362,000 after purchasing an additional 5,975 shares during the last quarter. Institutional investors own 83.70% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently commented on IRON shares. Morgan Stanley reiterated an "overweight" rating and issued a $90.00 price target on shares of Disc Medicine in a research note on Monday, August 17th. HC Wainwright upped their price objective on Disc Medicine from $118.00 to $120.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Wall Street Zen raised shares of Disc Medicine from a "sell" rating to a "hold" rating in a research report on Saturday, August 1st. Wedbush reaffirmed an "outperform" rating and set a $88.00 target price on shares of Disc Medicine in a report on Wednesday, June 10th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Disc Medicine in a research note on Friday, July 17th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $106.50.

About Disc Medicine

Disc Medicine, Inc NASDAQ: IRON is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source